Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study

Journal of Psychopharmacology
Yanling ZhouYuping Ning

Abstract

The long-term effects of dose reduction of atypical antipsychotics on cognitive function and symptomatology in stable patients with schizophrenia remain unclear. We sought to determine the change in cognitive function and symptomatology after reducing risperidone or olanzapine dosage in stable schizophrenic patients. Seventy-five stabilized schizophrenic patients prescribed risperidone (≥4 mg/day) or olanzapine (≥10 mg/day) were randomly divided into a dose-reduction group ( n=37) and a maintenance group ( n=38). For the dose-reduction group, the dose of antipsychotics was reduced by 50%; for the maintenance group, the dose remained unchanged throughout the whole study. The Positive and Negative Syndrome Scale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects, and Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery were measured at baseline, 12, 28, and 52 weeks. Linear mixed models were performed to compare the Positive and Negative Syndrome Scale, Negative Symptom Assessment-16, Rating Scale for Extrapyramidal Side Effects and MATRICS Consensus Cognitive Battery scores between groups. The linear mixed model showed significant time by group ...Continue Reading

References

Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Mar 1, 1995·Archives of General Psychiatry·R J Baldessarini, A C Viguera
May 19, 2000·The Journal of Clinical Psychiatry·H Y LaneW H Chang
Jun 1, 2000·The American Journal of Psychiatry·A KopelowiczJ Mintz
Jun 14, 2002·Biological Psychiatry·Michael F GreenJim Mintz
Jan 2, 2004·The American Journal of Psychiatry·Dennis S Charney
Jan 2, 2004·The American Journal of Psychiatry·Michael J MinzenbergSophia Vinogradov
Nov 9, 2004·Schizophrenia Research·Keith H NuechterleinRobert K Heaton
Mar 4, 2006·The American Journal of Psychiatry·Gary RemingtonShitij Kapur
Apr 29, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Nobutoshi KawaiTetsuya Iidaka
May 2, 2006·The American Journal of Psychiatry·Thomas H McGlashanAlan Breier
Oct 19, 2006·Journal of Psychopharmacology·Simon Burton
Oct 28, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Kara A BottiggiFrederick A Schmitt
Jan 4, 2008·The American Journal of Psychiatry·Keith H NuechterleinStephen R Marder
Jun 14, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Frédéric RouillonIsabelle Gasquet
Nov 17, 2009·Journal of Clinical Psychopharmacology·Hiroyuki UchidaDavid C Mamo
Dec 4, 2009·Schizophrenia Bulletin·Julie KreyenbuhlUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Dec 4, 2009·Schizophrenia Bulletin·Lisa B DixonUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
May 5, 2010·The American Journal of Psychiatry·Emma E M KnowlesAbraham Reichenberg
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Feb 9, 2011·Archives of General Psychiatry·Beng-Choon HoVincent Magnotta
Jun 23, 2011·Journal of Clinical Psychopharmacology·Hiroyuki UchidaDavid C Mamo
Jan 11, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yuya MizunoHiroyuki Uchida
Feb 1, 2012·Schizophrenia Bulletin·Hitoshi SakuraiHiroyuki Uchida
Nov 26, 2014·Schizophrenia Bulletin·Minna TorniainenJari Tiihonen

❮ Previous
Next ❯

Citations

Nov 27, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideaki TaniHiroyoshi Takeuchi
Feb 18, 2020·European Archives of Psychiatry and Clinical Neuroscience·Maximilian HuhnStefan Leucht
Jan 9, 2021·Behavioural Brain Research·Kazunari Yoshida, Hiroyoshi Takeuchi
Mar 30, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Esther Setién-SueroRosa Ayesa-Arriola
Jul 4, 2021·Asian Journal of Psychiatry·Juanjuan Ren, Chen Zhang

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

MATRICS
SPSS Statistics

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here